Novartis’s Capmatinib Shows High Response Rates In NSCLC
AACR Lung Cancer Plenary Also Included Spectrum’s Poziotinib
The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.
